Newly Approved Treatment for Hyperkalemia


Science & Innovation Theater Webinar 

Recorded on November 10, 2015 

Presented by Relypsa 

 Click here to download PDF of presentation 


Newly Approved Treatment for Hyperkalemia

Hyperkalemia is associated with increased risk of mortality, and is prevalent and recurrent in patients who suffer from cardio renal disorders including chronic kidney disease and heart failure. Please join us to review the latest innovation in Hyperkalemia treatment that impacts the management of CKD and HF patients.


Dr. Murray Epstein
Nephrologist, University of Miami
Background: Long-time thought leader in the fields of hypertension and renal function, authoring more than 400 journal articles & book chapters.

Sponsored by:

 Relypsa Logo 

This webinar is sponsored, developed and presented by the sponsor.  The content of the Science & Innovation Theater Webinars and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.